Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neovascular(Wet) Age Related Macular Degeneration”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Enrolling By InvitationNCT03999801
What this trial is testing

Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy

Who this might be right for
Neovascular Age-related Macular DegenerationWet Macular Degeneration
AbbVie 865
Testing effectiveness (Phase 2)Active Not RecruitingNCT05387837
What this trial is testing

Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME

Who this might be right for
Neovascular Age-related Macular DegenerationDiabetic Macular Edema
Ashvattha Therapeutics, Inc. 50
Testing effectiveness (Phase 2)Study completedNCT00320788
What this trial is testing

Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)

Who this might be right for
Macular Degeneration
Regeneron Pharmaceuticals 159
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05210803
What this trial is testing

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)
AbbVie 116
Testing effectiveness (Phase 2)Study completedNCT01535950
What this trial is testing

Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

Who this might be right for
Neovascular Age-elated Macular Degeneration (Wet AMD)Exudative Macular Degeneration
Novartis Pharmaceuticals 43
Testing effectiveness (Phase 2)Looking for participantsNCT05197270
What this trial is testing

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

Who this might be right for
Neovascular (Wet) Age-Related Macular Degeneration
4D Molecular Therapeutics 215
Large-scale testing (Phase 3)Not Yet RecruitingNCT07816315
What this trial is testing

Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04)

Who this might be right for
Wet Age Related Macular Degeneration
Ollin Biosciences, Inc. 500
Large-scale testing (Phase 3)Study completedNCT03823287
What this trial is testing

Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

Who this might be right for
Wet Macular Degeneration
Hoffmann-La Roche 671
Testing effectiveness (Phase 2)Study completedNCT04486963
What this trial is testing

A Phase Ⅱ Clinical Study of Sanhuangjingshimingwan in Wet( Neovascular)Age-related Macular Degeneration(wAMD) Subjects

Who this might be right for
Age-related Macular Degeneration
Tasly Pharmaceutical Group Co., Ltd 78
Large-scale testing (Phase 3)Active Not RecruitingNCT04704921
What this trial is testing

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

Who this might be right for
AMDnAMDWet Age-related Macular Degeneration+6 more
AbbVie 671
Testing effectiveness (Phase 2)Looking for participantsNCT06492863
What this trial is testing

Gene Therapy(FT-003) for Wet AMD

Who this might be right for
Neovascular Age-related Macular Degeneration
Frontera Therapeutics 78
Not applicableStudy completedNCT05131646
What this trial is testing

Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study

Who this might be right for
Neovascular Age-related Macular Degeneration
Clearside Biomedical, Inc. 15
Testing effectiveness (Phase 2)Study completedNCT01674569
What this trial is testing

Pilot Study of X-82 in Patients With Wet AMD

Who this might be right for
Exudative Macular Degeneration
Tyrogenex 35
Not applicableStudy completedNCT02173496
What this trial is testing

Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)

Who this might be right for
Age Related Macular Degeneration
Aston University 233
Not applicableStudy completedNCT01773954
What this trial is testing

Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration

Who this might be right for
Age-Related Macular DegenerationMacular Degeneration
MidAtlantic Retina 40
Early research (Phase 1)Study completedNCT03249740
What this trial is testing

A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration

Who this might be right for
Neovascular Age-Related Macular Degeneration
Graybug Vision 32
Early research (Phase 1)Study completedNCT01255462
What this trial is testing

Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration

Who this might be right for
Advanced Age-related Macular Degeneration
Novartis Pharmaceuticals 24
Not applicableStudy completedNCT05146687
What this trial is testing

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)

Who this might be right for
Age-related Macular Degeneration (AMD)
Novartis Pharmaceuticals 369,600
Large-scale testing (Phase 3)Not Yet RecruitingNCT07816289
What this trial is testing

Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05)

Who this might be right for
Wet Age-related Macular Degeneration
Ollin Biosciences, Inc. 400
Testing effectiveness (Phase 2)Ended earlyNCT01189019
What this trial is testing

HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration

Who this might be right for
Wet Macular DegenerationMacular DegenerationRetinal Pigment Epithelial Detachment
Anne Fung MD 40
Next Page